VistaGen Therapeutics Inc (NASDAQ: VTGN) has recently enjoyed extremely meaningful positive changes in investment behavior: its shorter term price trend turned up, its longer term price trend turned up, and the stock rose on very heavy volume.
Recent minimal positive changes in fundamentals have benefitted VistaGen Therapeutics Inc (NASDAQ: VTGN): the stock’s power rating rose above 70.
In light of these very positive signals we are reviewing our current Overall Rating of D. We would view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
With future capital returns forecasted to be below the cost of capital, VTGN is expected to be a modest Value Eraser.
VistaGen Therapeutics has a current Value Trend Rating of D (Negative). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. VistaGen Therapeutics has a very low Appreciation Score of 11 but a good Power Rating of 75, triggering the Negative Value Trend Rating.
Recent Price Action
VistaGen Therapeutics Inc (NASDAQ: VTGN) stock closed at $4.98 on 12/15/23 after a modest gain of 0.4%. Moreover, this advance was accompanied by exceptionally high trading volume at 323% of normal. The stock has risen 2.3% during the last week and has been exceptionally strong relative to the market over the last nine months.
Be the first to comment